Of mice and men. Blowing away the cobwebs from the mechanism of action of niacin on HDL mtabolism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 11, 2008, Pages 1892-1895

  Watts, G F ^a   Chan, D C ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; DIACYLGLYCEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN;

ATHEROSCLEROSIS; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; EDITORIAL; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER FUNCTION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; DISEASE MODEL; FAT INTAKE; GENETICS; HUMAN; KINETICS; LIVER; METABOLISM; MOUSE; NOTE; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DIETARY FATS; DISEASE MODELS, ANIMAL; HUMANS; KINETICS; LIVER; MICE; MICE, TRANSGENIC; NIACIN; TRIGLYCERIDES; UP-REGULATION;

EID: 55449091198     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.175224     Document Type: Editorial

References (21)

1. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
2. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199-2211.
3. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 2006;116:3090-3100.
4. Brown GB Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol. 2008;101:58-62.
5. van der Hoorn JWA, de Haan W, Berbée JFP, Havekes LM, Jukema JW, Rensen PCN, Princen HMG Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP mice. Arterioscler Thromb Vasc Biol. 2008;28:2016-2022.
6. Kamanna VS, Kashyap ML. Mechanisms of action of niacin. Am J Cardiol. 2008;101:20-26.
7. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest. 2000;105:513-520.
8. Lamon-Fava S, Diffenderfer MR, Barrett PHR, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schaefer FJ Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and apoB-containing lipoproteins. Arterioscler Thromb Vasc Biol. 2008;28:1672-1678.
9. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004;45:1835-1845.
10. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J Lipid Res. 2008;49:1195-1201.
11. Hernandez M, Wright SD, Cai TQ. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun. 2007;355:1075-1080.
12. Zadelaar S, Kleemann R, Verschuren L, J de Vries-Van der Weij, van der Hoorn J, Princen HM, Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007;27:1706-1721.
13. Blum CB, Levy RI, Eisenberg S, Hall M III, Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest. 1977;60:795-807.
14. Shepherd J, Packard CJ, Patsch JR, Gotto AM, Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 1979;63:858-867.
15. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglyceride in man. J Lipid Res. 1981;22:24-36.
16. Wang W, Basinger A, Neese RA, Shane B, Myong Su-A, Christiansen M, Hellerstein MK. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab. 2001;280:540-547.
17. Watts GF, Barren PHR, Chan DC. HDL metabolism in context: looking on the bright side. Curr Opin Lipidol. 2008;19:395-404.
18. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler Thromb Vasc Bol. 2005;25:2185-2191.
19. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, Lopez-Sendon, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
20. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370:1907-1914.
21. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Björkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25:1057-1064.